Cited by 57Genetic Neurodegenerative DiseasesNeurological diseases and metabolismPrion Diseases and Protein Misfolding

Neuroanatomic Profile of Polyglutamine Immunoreactivity in Huntington Disease Brains

Open access
Herndon, Emily S., Hladik, Christa L., Shang, Ping, Burns, Dennis K., Raisanen, Jack, White, Charles L.·2009·Journal of Neuropathology & Experimental Neurology

Abstract

A pathologic hallmark of Huntington disease (HD) is the presence of intraneuronal aggregates of polyglutamine-containing huntingtin protein fragments. Monoclonal antibody 1C2 is a commercial antibody to normal human TATA-binding protein that detects long stretches of glutamine residues. Using 1C2 as a surrogate marker formutant huntingtin protein, we immunostained 19 HD cases, 10 normal controls, and 10 cases of frontotemporal degeneration with ubiquitinated inclusions as diseased controls. In the HD cases, there was consistent 1C2 immunoreactivity in the neocortex, striatum, hippocampus, lateral geniculate body, basis pontis, medullary reticular formation, and cerebellar dentate nucleus. The normal and diseased controls demonstrated 1C2 immunoreactivity only in the substantia nigra, locus coeruleus, and pituitary gland. Staining of 5 HD cases and 5 normal controls revealed a less consistent and less diagnostically useful morphologic immunoreactivity profile. These results indicate that widespread 1C2 immunoreactivity is present in diverse central nervous system areas in HD, and that in the appropriate setting, 1C2 staining can be a useful tool in the postmortem diagnosis of HD when neuromelanin-containing neuronal populations are avoided.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e318198d320

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The 1C2 antibody detects polyQ expansions and is specific to the mutant protein.

    “The 1C2 antibody detects polyQ expansions33; and thus, is specific to the mutant protein.”

    From A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system (2019) · cites this paper as [33]

    The Introduction says 1C2 binds preferentially to long-glutamine-stretch-containing mutant huntingtin, supporting its use to detect polyQ expansions. It does not support specificity to the mutant protein: the antibody was raised against normal TATA-binding protein, and the Abstract reports 1C2 immunoreactivity in controls. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [1]The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 1993 72 971 983 8458085
  2. [3]Trottier Y Lutz Y Stevanin G Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias Nature 1995 378 403 406 7477379
  3. [4]Tibben A Bates G Harper P Jones L Genetic counselling and presymptomatic testing Huntington's Disease 2002 Oxford Oxford University Press 198 248
  4. [5]Jones L Bates G Harper P Jones L The cell biology of Huntington's disease Huntington's Disease 2002 Oxford Oxford University Press 348 386 5
  5. [6]DiFiglia M Sapp E Chase KO Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 1997 277 1990 1993 9302293
  6. [7]Sapp E Schwarz C Chase K Huntingtin localization in brains of normal and Huntington's disease patients Ann Neurol 1997 42 604 612 9382472
  7. [8]Becher MW Kotzuk JA Sharp AH Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length Neurobiol Dis 1998 4 387 397 9666478
  8. [9]Gourfinkel-An I Cancel G Duyckaerts C Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset Neuroreport 1998 9 1823 1826 9665608
  9. [10]Gutekunst CA Li SH Yi H Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology J Neurosci 1999 19 2522 2534 10087066 PMC6786077
  10. [11]Maat-Schieman ML Dorsman JC Smoor MA Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain J Neuropathol Exp Neurol 1999 58 129 137 10029096
  11. [12]Sieradzan KA Mechan AO Jones L Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein Exp Neurol 1999 156 92 99 10192780
  12. [13]Lunkes A Lindenberg K Ben-Haiem L Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions Mol Cell 2002 10 259 269 12191472
  13. [14]van Roon-Mom MCW Reid SJ Jones AL Insoluble TATA-binding protein accumulation in Huntington's disease cortex Mol Brain Res 2002 109 1 10 12531510
  14. [15]van Roon-Mom MCW Hogg VM Tippett LJ Aggregate distribution in frontal and motor cortex in Huntington's disease brain Neuroreport 2006 17 667 670 16603932
  15. [16]Maat-Schieman M Roos R Losekoot M Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease Brain Pathol 2007 17 31 37 17493035 PMC8095615
  16. [17]Schilling G Klevytska A Tebbenkamp A Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models J Neuropathol Exp Neurol 2007 66 313 320 17413322
  17. [18]Yamada M Tsuji S Takahashi H Pathology of CAG repeat diseases Neuropathol 2000 20 319 325 11211058
  18. [19]Rudnicki D Pletnikova O Vonsattel J-P A comparison of Huntington disease and Huntington disease-like 2 neuropathology J Neuropathol Exp Neurol 2008 67 366 374 18379432
  19. [20]Mackenzie IR Butland SL Devon RS Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease BMC Neurol 2006 6 1471 2377 PMC1570137 16945149
  20. [21]Vonsattel JP Myers RH Stevens TJ Neuropathological classification of Huntington's disease J Neuropathol Exp Neurol 1985 44 559 577 2932539
  21. [22]Dorsman J Pepers B Langenberg D Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells Hum Mol Genet 2002 11 1487 1496 12045202
  22. [23]Sugaya K Matsubara S Miyamoto K An aggregate-prone conformational epitope in trinucleotide repeat diseases Neuroreport 2003 14 2331 2335 14663186
  23. [24]Double K Zecca L Cost P Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins J Neurochem 2000 75 2583 2589 11080212
  24. [25]Butland S Devon R Huang Y CAG-encoded polyglutamine length polymorphism in the human genome BMC Genomics 2007 8 126 17519034 PMC1896166
  25. [26]Alafuzoff I Parkkinen L Al-Sarraj S Assessment of alpha-synuclein pathology: A study of the BrainNet Europe Consortium J Neuropathol Exp Neurol 2008 67 125 143 18219257
  26. [28]Osmand AP Berthelier V Wetzel R Imaging polyglutamine deposits in brain tissue Methods Enzymol 2006 412 106 122 17046655

Cited by

Sorted by citations

Authors
Herndon, E. S., Hladik, C. L., Shang, P., Burns, D. K., Raisanen, J., & White, C. L.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Herndon, Emily S.
Venue
Journal of Neuropathology & Experimental Neurology
Published
2009-03
Volume
68
Issue
3
Pages
250-261
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W2401722928
Cited by
57
References
1
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 5 · 2017: 2 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 4
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Chinese Academy of Agricultural Sciences
  • National Institute on Aging (P30AG012300, AG 12300)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
Keywords
Huntington's disease, mutant huntingtin, TATA-binding protein, postmortem diagnosis, striatum, neocortex, hippocampus, lateral geniculate nucleus, cerebellar dentate nucleus, frontotemporal lobar degeneration, ubiquitinated inclusions, neuromelanin
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Brain, Child, Female, Humans, Huntington Disease, Male, Middle Aged, Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review